Teva has long-term plans for the Russian market

Print 11 August 2017
GMP News

In its financial report for Q2 2017, Teva announced that it was curtailing the activities in 45 countries.

In this regard, Teva Russia made an official comment to clarify the following: the countries scheduled for business closure are mostly located in Africa and the Middle East, where the company’s presence is small.

The Russian office continues to operate as usual, without any changes in its operating activities. The company is successfully developing the local manufacturing at its plant in Yaroslavl and has long-term plans for the Russian market, which remains a strategic one for Teva.

Source

Return

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news